Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib... | NCT03129724 | Trialant
Unknown statusObservationalUpdated Apr 26, 2017
Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib
ClinicalTrials.gov ID
NCT03129724
Lead Sponsor
University Hospital, Strasbourg, FranceOTHER
Overall Status
Unknown status
Study Type
Observational
Enrollment
100Estimated
Last Update Posted
Apr 26, 2017Actual
Start Date
Sep 2016
Primary Completion Date
Jul 2017Estimated
Completion Date
Jul 2017Estimated
Brief Summary
Describe in patients with metastatic kidney cancer treatment modalities with the type sequences: TKI - mTORi - Axitinib or VEGF mAb - mTORi - Axitinib.
Kidney Neoplasms
No interventions
There are no interventions for this study.
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Patient with metastatic kidney cancer (all histological types)
Male or female aged (e) of 18 or more
Patient has been treated or under treatment with axitinib (Inlyta®) in the third line after the first line of targeted TKI therapy and after mTORi in 2nd line, or
Patient receiving the treatment sequence VEGFmAb - mTORi - axitinib For living patients: patient informed and having given oral consent
Exclusion criteria:
Patient who received more than one line of antiangiogenic therapy in the metastatic phase before initiation of treatment with axitinib (except patients in the study Pisces) Patient received a second line treatment with TKI Patient refused to participate in the study